Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 9/20 | 0.39 |
| ▸ | RARG | P13631 | 9/20 | 0.39 |
| ▸ | RARA | P10276 | 7/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 4/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517319 | 0.91 | RARA (0.36) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL4521601 | 0.88 | RARB (0.35) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL5736145 | 0.86 | RARB (0.56) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL4508292 | 0.86 | ACACB (0.36) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL6427644 | 0.83 | RARB (0.47) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL4813799 | 0.83 | RARB (0.39) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL5737238 | 0.81 | RXRA (0.39) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL4519859 | 0.80 | ACACB (0.32) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL5736448 | 0.80 | RARB (0.48) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL4502631 | 0.79 | RARB (0.36) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | CYP26B1, CYP2A6, CYP21A2 | RARB 11/4885RARG 19/4885RARA 14/4885 |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | RARB 595/4885RARG 546/4885RARA 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.